Skip to main content
. Author manuscript; available in PMC: 2022 Oct 11.
Published in final edited form as: Nat Cell Biol. 2022 Apr 11;24(4):554–564. doi: 10.1038/s41556-022-00877-0

Extended Data Figure 7. PRC2 loss of function mutations and the EED-KO gene signature associate with poor prognosis in breast cancer patients.

Extended Data Figure 7.

a, OncoPrint (cBioPortal) showing patients with loss of function mutations of PRC2 component genes in Metastatic Breast Cancer Project patient cohort. b, OncoPrint (cBioPortal) showing patients with amplification of PRC2 component genes in TCGA breast patient cohort. c, Kaplan-Meier survival (log rank Mantel-Cox test) of TCGA breast cancer patients with or without amplification of PRC2 component genes. d, A proportion of breast cancer patient-derived CTCs was associated with the EED-KO gene signature. scRNA-seq data were derived from GSE111065 dataset. Grey circles highlight CTCs associated with the EED-KO signature.